物归原主:淋巴细胞迁移机制参与原发性硬化性胆管炎的发病
原发性硬化性胆管炎(PSC)是胆管树的炎症性疾病,约70%病例合并炎症性肠病(IBD)。综述讨论肠-肝免疫交互在PSC-IBD中的作用,即肠道归巢淋巴细胞异常迁移至肝脏参与发病,并探讨干预这些迁移通路的药物(如维得利珠单抗、依曲利珠单抗)用于治疗PSC-IBD的潜在价值。
要点
- 约70%的PSC病例合并IBD,提示肠-肝免疫交互参与PSC-IBD发病。
- 肠道归巢淋巴细胞异常迁移至肝脏可能是PSC-IBD的发病机制之一。
- 干预淋巴细胞迁移通路的药物(如维得利珠单抗、依曲利珠单抗)是PSC-IBD的潜在治疗选择。
核心结论
- PSC是累及胆管树的炎症性疾病,以胆管狭窄性病变和进展为肝纤维化为特征,其病理生理机制仍不明确。
- 约70%的PSC病例合并IBD,由此提出肠道归巢淋巴细胞异常迁移至肝脏、参与PSC-IBD发病的假说。
- 淋巴细胞向靶组织的相互迁移通路以及肝脏中肠道特异性黏附分子和趋化因子的表达,为上述方向提供了依据。
- 目前对使用干预这些迁移通路的药物(如维得利珠单抗、依曲利珠单抗)治疗PSC-IBD的兴趣日益增加。
研究设计与样本
- 综述,讨论PSC合并IBD时肠与肝之间已知的免疫学交互,以及干预这些机制的潜在治疗选择。
主要发现
- 约70%的PSC病例合并IBD,支持肠道归巢淋巴细胞异常迁移至肝脏参与PSC-IBD发病的假说。
- 淋巴细胞向靶组织的相互迁移通路以及肝脏中肠道特异性黏附分子和趋化因子的表达,指向肠道归巢淋巴细胞异常迁移至肝脏这一方向。
- 干预淋巴细胞迁移通路的药物(如维得利珠单抗、依曲利珠单抗)用于治疗PSC-IBD受到越来越多的关注。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tree, characterised by stricturing bile duct disease and progression to liver fibrosis. The pathophysiology of PSC is still unknown. The concurrence with inflammatory bowel disease (IBD) in about 70% of cases has led to the hypothesis that gut-homing lymphocytes aberrantly traffic to the liver, contributing to disease pathogenesis in patients with both PSC and IBD (PSC-IBD). The discovery of mutual trafficking pathways of lymphocytes to target tissues, and expression of gut-specific adhesion molecules and chemokines in the liver has pointed in this direction. There is now increasing interest in using drugs that intervene with these trafficking pathways (e.g. vedolizumab, etrolizumab) for the treatment of PSC-IBD. In this review we discuss what is currently known about the immunological interactions between the gut and the liver in concomitant PSC and IBD, as well as potential therapeutic options for intervening in these mechanisms.
引用
- de Krijger M, Wildenberg ME, de Jonge WJ, et al. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol. 2019. PMID: 31108158. doi:10.1016/j.jhep.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。